|
|
|||
|
||||
OverviewThe study of tumour resistance to anticancer drugs has been the subject of many publications since the initial discovery of the phenomenon by J. H. Burchenal and colleagues in 1950. Many papers have been published since then reporting development of resistance to most of the well-known anticancer agents in many different animal tumour systems, both in vivo and in vitro. Many different mechanisms of resistance have been described, and it is clear that the tumour cell has a wide diversity of options in overcoming the cell-killing activity of these agents. Definition of the magnitude of the phenomenon in the clinic is, however, much more problematical, and it is with this in mind that the initial chapter, seeks to out line the problem as the clinicians see it. It appears that the phenomenon of true resistance to a drug, as the biochemist would recognise it, is an important cause of the failure which clinicians experience in treating the disease. The extent of the contribution of this phenomenon to the failure of treatment cannot easily be evaluated at the present time, but it is hoped that the development and application of new and more sophisticated techniques for the analysis of cellular sub populations may help to give a more exact estimate and to shed some light on the causes of failure of many of the present therapeutic techniques. Full Product DetailsAuthor: Brian W. Fox , N.K. Ahmed , M. Fox , B. BarlogiePublisher: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG Imprint: Springer-Verlag Berlin and Heidelberg GmbH & Co. K Edition: Softcover reprint of the original 1st ed. 1984 Volume: 72 Dimensions: Width: 17.00cm , Height: 3.90cm , Length: 24.40cm Weight: 1.306kg ISBN: 9783642694929ISBN 10: 3642694926 Pages: 738 Publication Date: 07 December 2011 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: Manufactured on demand We will order this item for you from a manufactured on demand supplier. Table of ContentsSection I: Concepts of Drug Resistance.- 1 Clinical Setting.- 2 Experimental Setting.- Section II: Modification of Host-Tumor Interaction.- 3 Drug Disposition and Pharmacology.- 4 Immunological Changes.- 5 The Molecular Basis of Genetically Acquired Resistance to Purine Analogues in Cultured Mammalian Cells.- Section III: Cellular Aspects.- 6 Cell Cycle Perturbation Effects.- 7 Tumour Resistance and the Phenomenon of Inflammatory-Cell Infiltration.- 8 Flow Cytometric Methods for Studying Enzyme Activity in Populations of Individual Cells.- 9 Chromosome Studies.- 10 Alterations of Drug Transport.- 11 Cell Hybridisation.- Section IV: Modification of Tumor Biochemistry.- 12 Drug Resistance and DNA Repair.- 13 Cyclic AMP and Prostaglandins.- 14 Properties of Mitochondria.- 15 Mechanism of “Resistance” Towards Specific Drug Groups.- 16 Nitrosoureas.- Section V: Antimetabolites.- 17 Antipurines.- 18 Ribofuranose-containing Analogues of Uridine and Cytidine.- 19 5-Halogenated Pyrimidines and Their Nucleosides.- 20 Resistance to Amino Acid Analogs.- 21 Alkaloids.- Section VI: Antifolates.- 22 Folate Antagonists.- 23 Steroids.- Section VII: Modification of Resistance.- 24 Collateral Sensitivity and Cross-Resistance.ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |